Article thumbnail
Location of Repository

Angiotensin converting enzyme and vascular endothelial growth factor responses to exercise training in claudicants: the role of ace inhibition

By P. Ng


Exercise training is well recognised as an effective treatment for intermittent claudication. The mechanism underlying exercise induced improvements is multi-factorial but remains poorly understood. Low angiotensin-converting enzyme (ACE) activity has been associated with enhanced responses to endurance training. Specifically, low ACE activity has been associated with improved muscle metabolism, endothelial function, and suppressed inflammatory responses; processes linked with exercise training benefits in claudicants. Furthermore, pharmacological inhibition of ACE has been associated with enhanced angiogenesis in animal models of ischaemia, secondary to increases in vascular endothelial growth factor (VEGF). In this study, 11 claudicants were randomised to 8 weeks of supervised exercise training (n=6) or exercise advice (n=5). Walking ability was recorded before and after this period, and blood samples taken. Reverse transcription polymerase chain reaction (RT-PCR) was used to determine the effects of exercise training on ACE, VEGF and VEGF receptor (VEGFR) gene expression, and enzyme-linked immunosorbant assays (ELISA) measured changes in ACE and VEGF protein levels. In another experiment, a cell culture model of hypoxia, utilising ECV 304 cells and diethylenetriamine-nitric oxide (DETA-NO), was used to study the effects of the ACE inhibitor ramiprilat on ACE and VEGF responses to hypoxia, using RT-PCR and ELISA. Supervised exercise improved claudication distance by 105 metres (p < 0.05) and maximum walking distance by 141 metres (p < 0.05). ACE mRNA expression increased 30%, VEGF121 expression 43% and VEGF165 expression 70% (all p < 0.05). Soluble VEGFR-1 mRNA expression increased by 63% and VEGFR-2 72% (both p < 0.05). ACE and VEGF protein levels remained comparatively stable. In the cell culture experiments, ramiprilat increased VEGF protein levels in hypoxia. Although a lack of experimental runs prevented statistical analysis, the results also suggest that ramiprilat has a stimulatory effect on ACE mRNA expression in hypoxia. Improvements in walking ability after exercise training are associated with increases in both VEGF and VEGF receptor expression. ACE inhibitors could play a role in improving claudication by potentiating increases in VEGF in addition to their known action of suppressing ACE activity

Publisher: UCL (University College London)
Year: 2009
OAI identifier:
Provided by: UCL Discovery

Suggested articles


  1. (1992). [An epidemiologic study of the value and limits of physical therapy/exercise therapy in Fontaine stage II arterial occlusive disease]. Vasa Suppl
  2. (1998). [Effect of hypoxia on angiotensin-converting enzyme activity and gene expression of intrapulmonary artery smooth muscle cells]. Sheng Li Xue Bao
  3. (1997). A comparative study of treadmill tests and heel raising exercise for peripheral arterial disease. Eur J Vasc Endovasc Surg
  4. (2000). A et al. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest
  5. (1995). A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.
  6. (1993). A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques
  7. (2005). Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease. Thorax
  8. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature
  9. (1994). ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group.
  10. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol
  11. (1991). Adaptive changes in the periphery and their therapeutic consequences.
  12. (1986). Adverse effects profile of sulfhydryl compounds in man.
  13. (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.
  14. (2003). Angioplasty (versus non surgical management) for intermittent claudication. Cochrane Database Syst Rev
  15. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science
  16. (2002). Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia.
  17. (1994). Angiotensin converting enzyme (kininase II) mRNA production and enzymatic activity in human peripheral blood monocytes are induced by GM-CSF but not by other cytokines.
  18. (1995). Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.
  19. (2000). Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia
  20. (1998). Angiotensin Iconverting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J Pharmacol Exp Ther
  21. (2002). Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest
  22. (1995). Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension
  23. (1998). Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res
  24. (2003). Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor-{kappa}B, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory Action. J Clin Endocrinol Metab
  25. (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev
  26. (1999). Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells.
  27. (2003). Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res
  28. (1999). Angiotensin receptors: molecular biology and signalling. Clin Exp Pharmacol Physiol
  29. (1998). Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure.
  30. (2000). Angiotensin-converting enzyme gene insertion/deletion polymorphism and carotid artery wall thickness in patients with peripheral arterial occlusive disease. Int Angiol
  31. (1998). Angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral arterial occlusive disease. Vasa
  32. (2001). Angiotensin-converting enzyme genotype and physical performance during US Army basic training.
  33. (2000). Angiotensin-converting enzyme ID polymorphism and fitness phenotype in the HERITAGE Family Study.
  34. (1995). Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation
  35. (2001). Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res
  36. (1994). Angiotensin-converting enzyme inhibition increases exercise tolerance and muscle blood flow in rats with peripheral arterial insufficiency.
  37. (1999). Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet
  38. (2000). Angiotensinconverting enzyme gene I/D polymorphism and carotid artery disease in renovascular hypertension.
  39. (2004). Angiotensinconverting enzyme is involved in outside-in signaling in endothelial cells. Circ Res
  40. (2002). Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res
  41. (2001). Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis
  42. (2005). Arteriolization of capillaries and FGF-2 upregulation in skeletal muscles of patients with chronic peripheral arterial disease. Microcirculation
  43. (2007). Arterioscler Thromb Vasc Biol
  44. (1988). Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound. Angiology
  45. (1999). Atherosclerosis--an inflammatory disease.
  46. (2004). Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation
  47. (1990). Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation
  48. (1998). Biochemical and inflammatory changes in the exercising claudicant. Vasc Med
  49. (1998). Borg's Perceived Exertion and Pain Scales. Human Kinetics;
  50. (2004). Bradykinin receptor gene variant and human physical performance.
  51. (2006). Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med
  52. (1985). Calf muscle adaptation to peripheral vascular disease. Cardiovasc Res
  53. (1985). Captopril for the treatment of patients with hypertension and peripheral vascular disease. Angiology
  54. (1986). Captopril in the treatment of hypertension associated with claudication.
  55. (1996). Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.
  56. (1999). Cardiol
  57. (1996). Cardiovascular effects of exercise: role of endothelial shear stress.
  58. (1998). Castellarin A et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes.
  59. (1993). Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys
  60. (2003). Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation
  61. (2004). Circ Res
  62. (2002). CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res
  63. (2002). Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet
  64. (2003). Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res
  65. (1989). Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebocontrolled trial. Circulation
  66. (2000). Control selection for RNA quantitation. Biotechniques
  67. (2004). Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts.
  68. (2003). DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. Heart
  69. (1999). DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension
  70. (1992). Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature
  71. (1988). Determinants of endurance in well-trained cyclists.
  72. (2006). Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
  73. (2001). Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection.
  74. (1997). Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk1/KDR, is up-regulated by hypoxia.
  75. (1995). Differentiation of endothelium.
  76. (1998). Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet
  77. (2002). Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol
  78. (2004). Does supervised exercise offer adjuvant benefit over exercise advice. Eur J Vasc Endovasc Surg
  79. (1992). Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology
  80. (2001). Downregulation of angiotensin-converting enzyme by tumor necrosis factor-alpha and interleukin-1beta in cultured human endothelial cells.
  81. (2005). Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol
  82. (1966). Effect of daily muscular exercise in patients with intermittent claudication. Lancet
  83. (1999). Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure.
  84. (2006). Effect of training on the response of plasma vascular endothelial growth factor to exercise in patients with peripheral arterial disease. Clin Sci (Lond)
  85. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
  86. (1996). Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. Int Angiol
  87. (2001). Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease.
  88. (1991). Effects of handrail support on claudication and hemodynamic responses to single-stage and progressive treadmill protocols in peripheral vascular occlusive disease.
  89. (1978). Effects of physical training in intermittent claudication.
  90. (1997). Effects of sulphydryl- and nonsulphydryl-containing ACE inhibitors on left ventricular relaxation in the isolated guinea pig heart. Endothelium
  91. (2004). Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.
  92. (1999). Elite athletes and the gene for angiotensin-converting enzyme.
  93. (2004). Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta
  94. (2002). Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension
  95. (2000). Endothelin regulates angiotensin-converting enzyme in the mouse kidney.
  96. (2004). Endovascular stents for intermittent claudication. Cochrane Database Syst Rev 2003;CD003228. 228 13
  97. (2002). Endurance enhancement related to the Human Angiotensin I-Converting Enzyme I-D polymorphism is not due to differences in the cardiorespiratory response to training.
  98. (2004). Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation
  99. (1978). Enzyme immunoassays with special reference to ELISA techniques.
  100. (1973). Enzyme studies in muscles of patients with intermittent claudication. Effect of training.
  101. (2005). Evaluation of the microcirculation in vascular disease. J Vasc Surg
  102. (2002). Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis.
  103. (2001). Exclusion of the ACE D/I gene polymorphism as a determinant of endothelial dysfunction. Hypertension
  104. (2003). Exercise for intermittent claudication. Cochrane Database Syst Rev
  105. (2001). Exercise for intermittent claudication. Supervised programmes should be universally available. BMJ
  106. (1994). Exercise in patients with intermittent claudication results in the generation of oxygen derived free radicals and endothelial damage. Adv Exp Med Biol
  107. (2000). Exercise limitation in health and disease.
  108. (2001). Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial.
  109. (1995). Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA
  110. (2000). Exercise training and peripheral vascular disease.
  111. (2000). Exercise training for claudicants: changes in blood flow, cardiorespiratory status, metabolic functions, blood rheology and lipid profile. Eur J Vasc Endovasc Surg
  112. (2002). Exercise training for claudication.
  113. (1997). Exercise training for intermittent claudication: does it adversely affect biochemical markers of the 247 exercise-induced inflammatory response? Eur J Vasc Endovasc Surg
  114. (1996). Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg
  115. (1996). Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg
  116. (1997). Experimental model of short-time exercise-induced preconditioning in POAD patients. Angiology
  117. (1999). expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol
  118. (2000). Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol
  119. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.
  120. (1988). Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study.
  121. (1993). Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res
  122. (2000). Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis? Circ Res
  123. (1996). flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis.
  124. (2004). Gene expression quantitation technology summary. Methods Mol Biol
  125. (2000). Gene-environment interactions and the response to exercise.
  126. (2005). Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes
  127. (2000). Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg
  128. (2002). Hart A et al. Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med
  129. (2004). Hepatocyte growth factor regulates angiotensin converting enzyme expression.
  130. (2004). HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis
  131. (2003). Historical perspective of the renin-angiotensin system. Mol Biotechnol
  132. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.
  133. (1997). Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology
  134. (2005). How to explain the differences between renin angiotensin system modulators.
  135. (1999). Human Angiotensin I-Converting Enzyme gene and endurance performance.
  136. (1998). Human gene for physical performance. Nature
  137. (2002). Human Performance: A Role for the ACE Genotype? Exerc Sport Sci Rev
  138. (1989). Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis.
  139. (2005). Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF1alpha and an autocrine angiotensin system.
  140. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
  141. (1996). Hypoxiainduced paracrine regulation of vascular endothelial growth factor receptor expression.
  142. (1999). Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell
  143. (1991). Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene
  144. (2002). Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart
  145. (1999). Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med
  146. (2005). Improved endothelium dependent vasodilation in endurance athletes and its relation with ACE I/D polymorphism. Circ J
  147. (1997). Improved walking economy in patients with peripheral arterial occlusive disease. Med Sci Sports Exerc
  148. (2004). Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet
  149. (1998). Increased vascularization in mice overexpressing angiopoietin-1. Science
  150. (2006). Induced angiogenesis under cerebral ischemia by cyclooxygenase 2 and hypoxia-inducible factor naked DNA in a rat indirect-bypass model. Neurosci Lett
  151. (1998). Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells.
  152. (2000). Induction of angiotensinconverting enzyme by oncostatin m in human endothelial cells. Cytokine
  153. (2002). Induction of hypoxiainducible factor-1alpha by transcriptional and translational mechanisms.
  154. (2004). Inflammatory markers and physical performance in older persons: the InCHIANTI study.
  155. (2000). Influence of upper- and lower-limb exercise training on cardiovascular function and walking distances in patients with intermittent claudication. J Vasc Surg
  156. (1997). Inhaled nitric oxide does not change transpulmonary angiotensin II formation in patients with acute respiratory distress syndrome. Chest
  157. (1991). Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man.
  158. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.
  159. (2004). Integrated analysis of genetic, genomic and proteomic data. Expert Rev Proteomics
  160. (2005). Integrating gene and protein expression data: pattern analysis and profile mining. Methods
  161. (1987). Intermittent claudication, exercise, and blood rheology. Circulation
  162. (2005). Intermittent claudication: exercise-increased walking distance is not related to improved cardiopulmonary fitness. Eur J Vasc Endovasc Surg
  163. (2006). Intermittent claudication. BMJ
  164. (1995). Invest
  165. (2006). Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res
  166. (2002). Ischaemic preconditioning of skeletal muscle. 1. Protection against the structural changes induced by ischaemia/reperfusion injury.
  167. (1998). Ischaemic preconditioning: present position and future directions. Cardiovasc Res
  168. (1996). Kininase II-Type Enzymes. Their Putative Role in Muscle Energy Metabolism. Diabetes
  169. (2002). Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan. Circ J
  170. (2001). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation
  171. (2003). Local renin-angiotensin systems: the unanswered questions.
  172. (2005). Long-term exercise training and angiotensin-converting enzyme inhibition differentially enhance myocardial capillarization in the spontaneously hypertensive rat.
  173. (2003). Maintaining data integrity in microarray data management. Biotechnol Bioeng
  174. (2002). Management of intermittent claudication.
  175. (2000). Matrix metalloproteinases: biologic activity and clinical implications.
  176. (1998). Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet
  177. (2001). Medical treatment of peripheral arterial disease and claudication.
  178. (2003). Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology
  179. (2001). Molecular mechanisms of blood vessel growth. Cardiovasc Res
  180. (2001). Muscle tissue adaptations to hypoxia.
  181. (1985). Neovascularization produced by angiotensin II.
  182. (2005). New cyclooxygenase-2 inhibitor DFU regulates vascular endothelial growth factor expression in rheumatoid synoviocytes. Immunol Lett
  183. (2005). New fACEs to the renin-angiotensin system. Physiology (Bethesda )
  184. (2004). Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol
  185. (2001). Nitric oxide synthases: structure, function and inhibition.
  186. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev
  187. (2005). No association between Angiotensin Converting Enzyme (ACE) gene variation and endurance athlete status in Kenyans. Comp Biochem Physiol A Mol Integr Physiol
  188. (2000). No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status.
  189. (2003). Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol
  190. (1990). Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene
  191. (2004). Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism. Cardiovasc Drugs Ther
  192. (1999). On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors.
  193. (1981). Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. Clin Sci (Lond)
  194. (2004). Papayeoryiou A et al. Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease. Vasc Med
  195. (1992). PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res
  196. (1988). Peripheral adaptations to low blood flow in muscle during exercise.
  197. (1998). Peripheral arterial insufficiency: mechanisms, natural history, and therapeutic options. Adv Intern Med
  198. (2003). Peripheral vascular disease in Type 2 diabetic Chinese patients: associations with metabolic indices, concomitant vascular disease and genetic factors. Diabet Med
  199. (2001). Perlmutter A et al. Bleomycin upregulates gene expression of angiotensin-converting enzyme via mitogenactivated protein kinase and early growth response 1 transcription factor.
  200. (1998). Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione.
  201. (2001). Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim
  202. (2002). Phorbol ester induction of angiotensin-converting enzyme transcription is mediated by Egr-1 and AP-1 in human endothelial cells via ERK1/2 pathway. Circ Res
  203. (1990). Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications. Clin Physiol Biochem
  204. (1996). Physiol
  205. (2001). Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem
  206. (1987). Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet
  207. (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
  208. (2001). Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res
  209. (2002). Progression of atherosclerosis in patients with peripheral arterial disease as a function of angiotensin-converting enzyme gene insertion/deletion polymorphism. Angiology
  210. (2000). Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? Heart
  211. (1969). Rapid preparation of lymphocytes for tissue-typing. Lancet
  212. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med
  213. (1999). Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease.
  214. (1989). Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury.
  215. (1999). Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol. Vasc Med
  216. (2001). Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension
  217. (2002). Respir Crit Care Med
  218. (2001). Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc Res
  219. (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med
  220. (2002). Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation
  221. (1999). Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr Top Pathol
  222. (1999). Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int
  223. (1995). Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest
  224. (2002). Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol
  225. (2006). Signaling by the angiotensin-converting enzyme. Circ Res
  226. (2001). Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res
  227. (2005). Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension
  228. (2003). Skeletal muscle RAS and exercise performance.
  229. (1998). spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung.
  230. (1990). Spontaneous transformation and immortalization of human endothelial cells.
  231. (1999). Sports Exerc
  232. (1995). Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol
  233. (1992). Stimulation of bovine pulmonary artery endothelial cell ACE by dexamethasone: involvement of steroid receptors.
  234. (2003). Stressing the system.
  235. (1991). Structure of the angiotensin Iconverting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene.
  236. (1994). Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation
  237. (2004). Surg
  238. (1999). Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell
  239. (2000). The ACE gene and muscle performance. Nature
  240. (2004). The ACE gene insertion/deletion polymorphism and elite endurance swimming.
  241. (2006). The angiotensin converting enzyme I/D polymorphism in long distance runners. J Sports Med Phys Fitness
  242. (2001). The angiotensin converting enzyme I/D polymorphism in Russian athletes.
  243. (2002). The angiotensin-converting-enzyme insertion/deletion polymorphism is not a risk factor for peripheral arterial disease. Atherosclerosis
  244. (2001). The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.
  245. (1997). The biology of vascular endothelial growth factor. Endocr Rev
  246. (2003). The biology of VEGF and its receptors. Nat Med
  247. (2000). The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death.
  248. (2003). The effect of peripheral percutaneous transluminal angioplasty on quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg
  249. (1988). The Evaluation of Exercise Performance in Patients with Peripheral Vascular Disease. J Cardiopulm Rehabil
  250. (1998). The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking? Eur J Vasc Endovasc Surg
  251. (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.
  252. (2003). The I allele of the angiotensin-converting enzyme gene is associated with an increased percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet
  253. (2007). The impact of ACE genotype on serum ACE activity in a black South African male population.
  254. (1994). The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa
  255. (2001). The interaction between the reninangiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes.
  256. (1997). The origin of symptoms in chronic heart failure. Heart
  257. (2003). The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. Vasc Med
  258. (2001). The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.
  259. (2003). The renin-angiotensin and the kallikrein-kinin systems.
  260. (1996). The renin-angiotensin system and the heart: a historical review. Heart
  261. (2002). The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol
  262. (2006). The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci
  263. (2004). The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype.
  264. (2001). The splice variants of vascular endothelial growth factor (VEGF) and their receptors.
  265. (2003). The use of dimethylsulfoxide as a vehicle in cell culture experiments using ovarian carcinoma cell lines. Biotech Histochem
  266. (1999). Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation
  267. (1999). Trans-atlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology. Eur J Vasc Endovasc Surg
  268. (1998). Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol
  269. (1998). UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ
  270. (1998). Unstable atherosclerotic plaque. Pathophysiology and therapeutic guidelines. Acta Cardiol
  271. (1998). Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells. Cardiovasc Res
  272. (2001). Upregulation of angiotensinconverting enzyme by vascular endothelial growth factor.
  273. (1998). Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta
  274. (1995). Vascular Clinical Trialists. Circulation
  275. (1999). Vascular endothelial growth factor (VEGF) and its receptors.
  276. (1998). Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer.
  277. (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med
  278. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
  279. (2006). Vascular endothelial growth factor mRNA and protein do not change in parallel during noninflammatory skeletal muscle ischaemia in rat.
  280. (2003). Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res
  281. (2003). VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans
  282. (2000). VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol
  283. (2002). Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J Pharmacol Exp Ther
  284. (2005). vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: a randomized controlled trial. J Vasc Surg
  285. (1998). Zioncheck TF. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.